• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Melatonin vs Memantine for ECT-Related Cognitive Impairment

Melatonin vs Memantine for ECT-Related Cognitive Impairment

September 13, 2021
Anne Li, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Sarraf N et al, J Clin Neurosci 2020;74:146–150

Many patients hesitate to accept ECT because of the treatment’s adverse effects on cognitive function. Memantine (Namenda)—an NMDA receptor antagonist approved for the treatment of Alzheimer’s disease—has been shown to be more effective than placebo in preventing cognitive impairment due to ECT. A new study compares memantine with melatonin in depressed patients undergoing this treatment.

The authors conducted a randomized, double-blind trial to compare the effects of the two medications on patients with major depression who were undergoing ECT. Patients in the two medication groups were similar in demographic characteristics, duration of major depression, and scores on the Mini-Mental Status Examination (MMSE). All patients received right unilateral ECT with similar stimulus intensity, frequency, and duration. Melatonin was chosen as a comparative treatment because a previous study reported that it appeared effective at reducing ECT-induced cognitive impairment (Hamdieh M et al, Neurol Psych Brain Res 2017;24:30–34).

A total of 40 patients were randomized to receive either memantine 5 mg/day (n = 20) or melatonin 3 mg/day (n = 20), starting on the day of the first ECT treatment and ending on the day of the sixth treatment. ECT was administered every other day, and the trial lasted 12 days. The researchers administered the MMSE and item 3 of the MMSE—a measurement of immediate recall—a day before the first ECT treatment and again 24 hours after completion of the last ECT treatment.

At the conclusion of ECT, participants receiving memantine scored significantly higher than their baseline scores on both the MMSE and item 3 of the MMSE (p = 0.04 and p = 0.03, respectively). In contrast, participants’ scores in the melatonin group dropped on both measures compared to their baselines (MMSE, p = 0.3, and item 3 of the MMSE, p = 0.02).

Study subjects tolerated the medications well. A previous placebo-controlled study similarly found that memantine 5 mg/day reduced cognitive impairment following ECT (Abbasinazari M et al, Asian J Psychiatr 2015;15:5–9).

CHPR’s TAKE
Patients are often reluctant to accept ECT because of its effects on cognition. By prescribing memantine 5 mg/day, we may be able to forestall those effects and improve ECT’s acceptability. While previous research has found that melatonin also helps mitigate ECT-induced cognitive impairment, this study did not, possibly because the melatonin was administered in the morning and may have caused sedation.
Hospital Psychiatry
KEYWORDS cognitive-impairment ect melatonin memantine
    Anne Li, MD.

    Clozapine for Conduct Disorder in Schizophrenia

    More from this author
    www.thecarlatreport.com
    Issue Date: September 13, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Agitation, CHPR, October-November-December 2021
    Note From the Editor-in-Chief
    IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
    Can We Treat Depression by Targeting Inflammation?
    Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
    Melatonin vs Memantine for ECT-Related Cognitive Impairment
    Rapid-Onset Treatment for Pedophilic Disorder
    Medications to Rapidly Treat Psychotic Agitation
    Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
    Treating Agitation in Patients with Dementia
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.